Amphastar Pharmaceuticals, Inc. (AMPH)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$25.37−0.24%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.1B
- P/E (trailing)
- 15.0
- Forward P/E
- 8.0
- 52-week range
- $16.65 – $29.52
- 52-week change
- −1.55%
- EPS (trailing)
- $1.69
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $720M (−1.65%)
- Net income
- $98.1M
- Operating margin
- 19.5%
- Diluted EPS
- $2.03
- Free cash flow
- $121M
From the company’s annual report on SEC EDGAR.
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Headquarters: Rancho Cucamonga, United States · 1,976 employees · amphastar.com